Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone sodium phosphate vs dexamethasone palmitate for perioperative pain in knee arthroplasty
KCT0009362Phase 4
Key facts
- Status
- Not yet recruiting
- Start
- Apr 2024
- Countries
- 1
- Sponsor
- Kyongbo Pharm
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Conditions
- arthritispostoperative pain
01
Overview
Phase 4, randomised, double-blind trial of dexamethasone sodium phosphate and dexamethasone in arthritis and postoperative pain (2 arms), sponsored by Kyongbo Pharm. Primary endpoint: Perioperative pain control efficacy. Planned start Apr 2024; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Dexamethasone sodium phosphate arm
Participants receive dexamethasone sodium phosphate for perioperative pain management around knee joint arthroplasty.
Dexamethasone palmitate arm
Participants receive dexamethasone palmitate for perioperative pain management around knee joint arthroplasty.
03
Who it enrols
Adult Korean patients with arthritis undergoing knee joint arthroplasty; detailed inclusion and exclusion criteria are not reported.
04
Endpoints
Primary
Perioperative pain control efficacy
Beyond the preview
Go deeper on KCT0009362.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009362.